CSIMarket
 
Rezolute Inc   (RZLT)
Other Ticker:  
 
 
Price: $1.7800 $-0.04 -2.198%
Day's High: $1.85 Week Perf: -11 %
Day's Low: $ 1.66 30 Day Perf: 43.55 %
Volume (M): 357 52 Wk High: $ 2.42
Volume (M$): $ 635 52 Wk Avg: $1.50
Open: $1.83 52 Wk Low: $0.10



 Market Capitalization (Millions $) 92
 Shares Outstanding (Millions) 51
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -57
 Cash Flow (TTM) (Millions $) -134
 Capital Exp. (TTM) (Millions $) 0

Rezolute Inc
Rezolute Inc is a clinical-stage biopharmaceutical company that is focused on the development of drugs for the treatment of rare and metabolic diseases. The company's mission is to develop and commercialize therapies that can improve the lives of patients who suffer from rare diseases.

Founded in 2010, Rezolute Inc is headquartered in Redwood City, California. The company has a highly experienced management team that consists of industry veterans with a track record of success in drug development and commercialization.

Rezolute Inc is primarily focused on the development of two drug candidates, RZ358 and RZ40 RZ358 is a potential treatment for congenital hyperinsulinism (CHI), a rare genetic disorder that affects infants and children. RZ402 is a potential treatment for diabetic foot ulcers (DFU), a complication of diabetes that can lead to amputation.

The company's lead drug candidate, RZ358, is currently in a Phase 2b clinical trial for the treatment of CHI. Rezolute Inc has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for RZ358.

RZ402 is currently in pre-clinical development for the treatment of DFU. The company has received Orphan Drug Designation from the FDA for RZ40

Rezolute Inc has a partnership with Teva Pharmaceuticals, a leading global pharmaceutical company, for the development and commercialization of RZ358. The partnership includes an up-front payment to Rezolute Inc, as well as development and commercialization milestones.

In addition to its drug development programs, Rezolute Inc has a research collaboration with the Stanford University School of Medicine on the development of an implantable insulin pump for the treatment of diabetes.

Overall, Rezolute Inc is a promising biopharmaceutical company that is focused on developing innovative therapies for patients who suffer from rare and metabolic diseases. With its experienced management team, strong pipeline of drug candidates, and strategic partnerships, the company is well positioned for future success in the industry.


   Company Address: 275 Shoreline Drive, Suite 500 Redwood City 94065 CA
   Company Phone Number: 206-4507   Stock Exchange / Ticker: NASDAQ RZLT
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Expanding the Potential of RZ358 and Promising Advances in Diabetic Macular Edema Treatment

Published Wed, Mar 6 2024 12:30 PM UTC

In recent studies, pharmaceutical company Rezolute has made significant progress in the development of two potential treatments for different medical conditions - RZ358 for Non-Islet Cell Tumor Hypoglycemia (NICTH) and a Phase 2 study for Diabetic Macular Edema (DME). These developments hold great promise for expanding the addressable patient population and improving treatme...

Rezolute Inc

Existing Expenditures Accumulate at Rezolute Inc in the Financial Period Ending December 31, 2023



Leading pharmaceutical preparations sector advisors are currently analyzing Rezolute Inc's financial results for the second quarter of 2024. Despite reporting an operating deficit of $-15.194 million, the company has not yet disclosed any top-line figures for the October to December 31, 2023 reporting season. However, stakeholders are optimistic about the potential for additional revenue streams in the near future. While productivity improvement is not currently relied upon, Rezolute Inc is exploring different business models to ensure consistent growth.
Financial Performance and Operational Deficit:
During the development stage, Rezolute Inc faced a deficit of $-13.556 million in the second quarter of 2023. However, this deficit has extended to $-13.909 million over the same period in the recent reporting season. The operating deficit for the second quarter of 2024 stands at $-15.194 million.
Biotechnology's Ambitious Phase 3 Clinical Trial:
Rezolute Inc recently gained attention by embarking on a Phase 3 clinical trial for RZ358, a pioneering therapy designed to address Congenital Hyperinsulinism (CHI), a rare genetic disease. This move has shed light on the field of rare metabolic disorders and offers hope for delivering a ground-breaking solution within the next five years. The clinical trial is a significant development for both the biotechnology industry and families affected by CHI.
Implication for Future Results:
Rezolute Inc's focus on developing innovative therapies for serious metabolic and rare diseases demonstrates a commitment to driving positive change in the healthcare industry. The Phase 3 clinical trial for RZ358 signifies the company's dedication to tackling unmet medical needs in a previously overlooked field. If successful, this trial has the potential to revolutionize treatment options and significantly improve the lives of individuals living with CHI.

Clinical Study

A Leap Forward: Rezolute Gears Up for Pivotal Phase 3 Clinical Trial Targeting Congenital Hyperinsulinism

Published Thu, Dec 14 2023 1:00 PM UTC


Biotechnology veteran Rezolute, Inc. recently made headlines by entering into an ambitious Phase 3 clinical trial for RZ358, a pioneer therapy targeted at individuals living with the rare, genetic disease called Congenital Hyperinsulinism (CHI). This audacious initiative puts a spotlight on an overlooked field of medicine ?? rare metabolic disorders, and powers the hope...

Clinical Study

Visionary Progress: Rezolute's Revolutionary Study Nears Completion, Paving the Way for Groundbreaking Diabetic Macular Edema Treatments

Published Wed, Dec 13 2023 1:00 PM UTC



In a significant milestone for medical research, Rezolute, a prominent biopharmaceutical company, has recently achieved the completion of patient enrollment for its Phase 2 study on Diabetic Macular Edema (DME). This crucial trial aims to evaluate the safety and efficacy of a potential breakthrough treatment, bringing hope to millions of individuals worldwide suffe...

Rezolute Inc

Rezolute Inc Dazzles with Impressive First Quarter 2024 Results, Surpassing Expectations Amongst Competitors

Rezolute Inc, a major pharmaceutical preparations company, is facing several challenges according to the recently released financial reports for the period between July and September 2023. Investors were not anticipating any significant changes during this reporting season, but were surprised by the company's operating shortfall amounting to a substantial $-15.914 million.
Comparing this to the previous year's first quarter report, where the operating shortfall stood at $-10.218 million, it is clear that Rezolute Inc has been struggling to improve its financial performance. The company now finds itself with a widening deficit of $-14.524 million, compared to $-9.831 million in the same period a year earlier, indicating a deteriorating financial situation.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com